Breast Cancer: Triple - Negative: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Breast Cancer: Triple - Negative: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need.

This report addresses the following questions:

- Which branded therapies will have the largest commercial potential in the triple-negative breast cancer market?
- What impact will immunotherapies have on treatment algorithms in triple-negative breast cancer?
- How will competing poly (ADP-ribose)polymerase (PARP) inhibitors Lynparza, niraparib, talazoparib, and veliparib fare against one another?
- How will pipeline therapies aim to address areas of unmet need?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abraxane (albumin-bound paclitaxel)
- Atezolizumab
- Avastin (bevacizumab)
- glembatumumab vedotin
- Halaven (eribulin mesylate)
- Keytruda (pembrolizumab)
- Lynparza (olaparib)
- Niraparib
- sacituzumab govitecan
- Talazoparib
- Veliparib
- Primary Research Methodology

TREATMENT: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Disease Definition and Diagnosis
- Primary Research Methodology
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in Triple-Negative Breast Cancer

EPIDEMIOLOGY: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Product Overview
- Product profile: Abraxane
- Product profile: Avastin
- Product profile: Halaven

PIPELINE: TRIPLE-NEGATIVE BREAST CANCER

- Executive Summary
- Clinical Pipeline Overview
- Target Product Profile
- Product profile (late stage): Keytruda
- Product profile (late stage): Lynparza
- Product profile (late stage): atezolizumab
- Product profile (late stage): glembatumumab vedotin
- Product profile (late stage): niraparib
- Product profile (late stage): sacituzumab govitecan
- Product profile (late stage): talazoparib
- Product profile (late stage): veliparib

For more information about this report visit http://www.researchandmarkets.com/research/l9xbz2/breast_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Women's Health, Breast Cancer Drugs